Eudocia Q. Lee
A5035087247- Glioma Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Research Studies
- Histone Deacetylase Inhibitors Research
- Radiomics and Machine Learning in Medical Imaging
- Meningioma and schwannoma management
- Cancer Immunotherapy and Biomarkers
- Nanoplatforms for cancer theranostics
- Computational Drug Discovery Methods
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- CAR-T cell therapy research
- Management of metastatic bone disease
- Immune cells in cancer
- Cancer Research and Treatments
- Statistical Methods in Clinical Trials
- Advanced Breast Cancer Therapies
- Neuroblastoma Research and Treatments
- Protein Degradation and Inhibitors
- Nanoparticle-Based Drug Delivery
- Health Systems, Economic Evaluations, Quality of Life
- CNS Lymphoma Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
Dana-Farber Cancer Institute
2016-2025
Harvard University
2016-2025
Center for Neuro-Oncology
2016-2025
Brigham and Women's Hospital
2016-2025
Dana-Farber Brigham Cancer Center
2014-2024
Boston University
2022-2023
Massachusetts General Hospital
2014-2021
Duke Medical Center
2021
Ludwig-Maximilians-Universität München
2021
Duke Cancer Institute
2021
Brain metastases are associated with significant morbidity and mortality. Population-level data describing the incidence prognosis of patients brain lacking. The aim this study was to characterize at diagnosis systemic malignancy using recently released from Surveillance, Epidemiology, End Results (SEER) program.
Population-based estimates of the incidence and prognosis brain metastases at diagnosis breast cancer are lacking.To characterize proportions median survivals patients with time diagnosis.Patients were identified using Surveillance, Epidemiology, End Results (SEER) database National Cancer Institute. Data stratified by subtype, age, sex, race. Multivariable logistic Cox regression performed to identify predictors presence factors associated all-cause mortality, respectively. For incidence,...
No proven effective medical therapy for surgery and radiation-refractory meningiomas exists. Sunitinib malate (SU011248) is a small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) platelet-derived receptor, abundant in meningiomas.This was prospective, multicenter, investigator-initiated single-arm phase II trial. The primary cohort enrolled patients with recurrent World Health Organization (WHO) grades II-III meningioma. An exploratory WHO...
Abstract Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM) 1,2 . Here we report results a first-in-human phase I trial in 41 patients with rGBM who were injected CAN-3110—an oncolytic herpes virus (oHSV) 3 In contrast to other clinical oHSVs, CAN-3110 retains viral neurovirulence ICP34.5 gene transcribed by nestin promoter; is overexpressed GBM and invasive tumours, but not...
BACKGROUND The prognosis for patients with atypical and malignant meningioma is guarded; whether the extent of resection associated survival‐based outcomes in this population remains poorly defined. This study investigated association between gross total (GTR) all‐cause mortality meningioma. METHODS Surveillance, Epidemiology, End Results program was used to identify 575 64 betweens ages 18 70 years who were diagnosed meningioma, respectively, 2004 2009. Multivariate Cox proportional hazards...
Phosphatidylinositol 3-kinase (PI3K) signaling is highly active in glioblastomas. We assessed pharmacokinetics, pharmacodynamics, and efficacy of the pan-PI3K inhibitor buparlisib patients with recurrent glioblastoma PI3K pathway activation.This study was a multicenter, open-label, multi-arm, phase II trial pathway-activated at first or second recurrence. In cohort 1, scheduled for re-operation after progression received 7 to 13 days before surgery evaluate brain penetration modulation...
To evaluate whether the use of Bayesian adaptive randomized (AR) designs in clinical trials for glioblastoma is feasible and would allow more efficient trials.
<h3>Objective:</h3> A subset of meningiomas recur after surgery and radiation therapy, but no medical therapy for recurrent meningioma has proven effective. <h3>Methods:</h3> Pasireotide LAR is a long-acting somatostatin analog that may inhibit growth. This was phase II trial in patients with histologically confirmed or progressive designed to evaluate whether pasireotide prolongs progression-free survival at 6 months (PFS6). Patients were stratified by histology (atypical [World Health...
Vorinostat, a histone deacetylase (HDAC) inhibitor, has shown radiosensitizing properties in preclinical studies. This open-label, single-arm trial evaluated the maximum tolerated dose (MTD; phase I) and efficacy (phase II) of vorinostat combined with standard chemoradiation newly diagnosed glioblastoma. Patients received oral (300 or 400 mg/day) on days 1–5 weekly during temozolomide chemoradiation. Following 4- to 6-week rest, patients up 12 cycles adjuvant (400 1–7 15–21 each 28-day...